BRAXIA SCIENTIFIC CORP.
Research BRAXIA SCIENTIFIC CORP. (4960) on Bullrun: market cap EUR 566.56K. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker4960
- ExchangeF
- CountryCanada
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 566.56K
- Financial periodFY2023
- RevenueCAD 1.88M
- Revenue growth26.7%
- Net income-CAD 13.14M
- Free cash flow-CAD 8.30M
- Gross margin9.1%
Valuation Snapshot
latest market cap is EUR 566.56K.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2023 | CAD 1.88M | -CAD 13.14M | -CAD 8.30M | 9.1% | -0.06 | CAD 1.46M | CAD 207.16K | CAD 1.60M |
| FY2022 | CAD 1.49M | -CAD 12.13M | -CAD 4.54M | 16.6% | -0.07 | CAD 8.68M | CAD 217.06K | CAD 8.96M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-18 | EUR 566.56K | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About BRAXIA SCIENTIFIC CORP.
Braxia Scientific Corp. operates as a medical research company with clinics that provide ketamine treatments for persons with depression and related disorders. The company also owns and operates multidisciplinary clinics that offers treatment of mental health disorders. In addition, it is involved in the research activities related to discovering and commercializing novel drugs and delivery methods;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is BRAXIA SCIENTIFIC CORP.'s market cap?
BRAXIA SCIENTIFIC CORP.'s market capitalization is EUR 566.56K.
What does BRAXIA SCIENTIFIC CORP. do?
Braxia Scientific Corp. operates as a medical research company with clinics that provide ketamine treatments for persons with depression and related disorders. The company also owns and operates multidisciplinary clinics that offers treatment of mental health disorders. In addition, it is involved in the research activities related to discovering and commercializing novel drugs and delivery methods; and development and acquisition of derivatives of ketamine and psilocybin, as well as other psychedelic products from its IP development platform. The company is headquartered in Toronto, Ontario.